Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

Vogt Koyanagi Harada Disease Clinical Trial

Official title:

Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00407121
• Other study ID #: APEC-0025
• Status: Withdrawn
• Phase: Phase 3
• Start date: December 2006
• Est. completion date: December 2006

Study information

• Verified date: May 2024
• Source: Asociación para Evitar la Ceguera en México
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2006
• Est. primary completion date: December 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 25 Years to 60 Years

Eligibility

Inclusion Criteria:

• Clinical Diagnose

• Patient Consent

• Chronic stage of inflammation

Exclusion Criteria:

• only eye

• age lower than 30 yo.

• Systemic condition

Related Conditions & MeSH terms

• Choroiditis
• Multifocal Choroiditis
• Serpiginous Choroiditis
• Uveomeningoencephalitic Syndrome
• Vogt Koyanagi Harada Disease

Intervention

Drug:
• Bevacizumab

Procedure:
• Intravitreal Injection of Bevacizumab

Locations

Country	Name	City	State
Mexico	Asociacion para Evitar la Ceguera en Mexico	Mexico	Distrito Federal

Sponsors (1)

Lead Sponsor	Collaborator
Asociación para Evitar la Ceguera en México

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Best corrected visual acuity
Primary	Retinal thickness by OCT
Primary	Leakage in Fluorescein angiogram